229 related articles for article (PubMed ID: 9212478)
21. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain.
Allan L; Richarz U; Simpson K; Slappendel R
Spine (Phila Pa 1976); 2005 Nov; 30(22):2484-90. PubMed ID: 16284584
[TBL] [Abstract][Full Text] [Related]
22. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine.
Payne R; Mathias SD; Pasta DJ; Wanke LA; Williams R; Mahmoud R
J Clin Oncol; 1998 Apr; 16(4):1588-93. PubMed ID: 9552070
[TBL] [Abstract][Full Text] [Related]
23. A comparison of the resources used in advanced cancer care between two different strong opioids: an analysis of naturalistic practice in the UK.
Guest JF; Ruiz FJ; Russ J; Gupta RD; Mihai A; Greener M
Curr Med Res Opin; 2005 Feb; 21(2):271-80. PubMed ID: 15801998
[TBL] [Abstract][Full Text] [Related]
24. Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study.
Mercadante S; Adile C; Cuomo A; Aielli F; Cortegiani A; Casuccio A; Porzio G
J Pain Symptom Manage; 2015 Nov; 50(5):579-86. PubMed ID: 26303188
[TBL] [Abstract][Full Text] [Related]
25. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Sittl R; Likar R; Nautrup BP
Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
[TBL] [Abstract][Full Text] [Related]
26. Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study.
Ridgway D; Sopata M; Burneckis A; Jespersen L; Andersen C
J Pain Symptom Manage; 2010 Apr; 39(4):712-20. PubMed ID: 20413058
[TBL] [Abstract][Full Text] [Related]
27. [Usefulness of fentanyl patch (Durotep) in cancer patients when rotated from morphine preparations].
Akiyama Y; Iseki M; Izawa R; Ishii K; Miyazaki T; Yamaguchi S; Tani Y
Masui; 2007 Mar; 56(3):317-23. PubMed ID: 17366919
[TBL] [Abstract][Full Text] [Related]
28. The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain.
Kang JH; Oh SY; Song SY; Lee HY; Kim JH; Lee KE; Lee HR; Hwang IG; Park SH; Kim WS; Park YS; Park K
Korean J Intern Med; 2015 Jan; 30(1):88-95. PubMed ID: 25589840
[TBL] [Abstract][Full Text] [Related]
29. [Transdermal fentanyl for the management of cancer pain: a survey of 4492 patients].
Yu SY; Sun Y; Wu YL; Qin SK; Xie GR; Liu SJ; Sui GJ; Zhang HC
Zhonghua Zhong Liu Za Zhi; 2005 Jun; 27(6):369-72. PubMed ID: 16117902
[TBL] [Abstract][Full Text] [Related]
30. Predicting long-term response to strong opioids in patients with low back pain: findings from a randomized, controlled trial of transdermal fentanyl and morphine.
Kalso E; Simpson KH; Slappendel R; Dejonckheere J; Richarz U
BMC Med; 2007 Dec; 5():39. PubMed ID: 18154644
[TBL] [Abstract][Full Text] [Related]
31. Long-term cancer pain management in morphine pre-treated and opioid naive patients with transdermal fentanyl.
Mystakidou K; Tsilika E; Parpa E; Kouloulias V; Kouvaris I; Georgaki S; Vlahos L
Int J Cancer; 2003 Nov; 107(3):486-92. PubMed ID: 14506751
[TBL] [Abstract][Full Text] [Related]
32. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
[TBL] [Abstract][Full Text] [Related]
33. [Comparison of transdermal fentanyl for the management of cancer pain in adults and elders].
Bilen A; Ali A; Alkan I; Altan A
Agri; 2012; 24(3):111-6. PubMed ID: 22865517
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of fentanyl HCl iontophoretic transdermal system compared with morphine intravenous patient-controlled analgesia for postoperative pain management for patient subgroups.
Mattia C; Coluzzi F; Sonnino D; Anker-Møller E
Eur J Anaesthesiol; 2010 May; 27(5):433-40. PubMed ID: 20186064
[TBL] [Abstract][Full Text] [Related]
35. Transdermal fentanyl in the management of children with chronic severe pain: results from an international study.
Finkel JC; Finley A; Greco C; Weisman SJ; Zeltzer L
Cancer; 2005 Dec; 104(12):2847-57. PubMed ID: 16284992
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials.
Jandhyala R; Fullarton JR; Bennett MI
J Pain Symptom Manage; 2013 Oct; 46(4):573-80. PubMed ID: 23380337
[TBL] [Abstract][Full Text] [Related]
37. [Concomitant use of strong and weak opioids in the management of chronic cancer pain].
Bilen A; Ali A; Baturay F; Ozcan B; Altan A
Agri; 2013; 25(1):7-12. PubMed ID: 23588864
[TBL] [Abstract][Full Text] [Related]
38. [Transdermal opioid administration: the pain plaster].
Vecht CJ; Sillevis Smitt PA
Ned Tijdschr Geneeskd; 1997 Apr; 141(17):821-3. PubMed ID: 9221362
[TBL] [Abstract][Full Text] [Related]
39. [Transdermal fentanyl for the management of cancer pain: a survey of 1,664 elderly patients].
Yu SY; Sun Y; Zhang HC; Wu YL; Qin SK; Xie GR; Liu SJ; Sui G
Zhonghua Yi Xue Za Zhi; 2003 Nov; 83(22):1931-5. PubMed ID: 14703423
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the Quality of Life of Cancer Patients with Pain Treated with Oral Controlled-Release Morphine and Oxycodone and Transdermal Buprenorphine and Fentanyl.
Leppert W; Nosek K
Curr Pharm Des; 2019; 25(30):3216-3224. PubMed ID: 31333114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
